# Aerovate Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerovate-therapeutics

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.aerovatetx.com
- Total disclosed funding: $73M
- Latest round: Series A (Aug 6, 2020)
- Investors on record: 6

## About

Founded in 2018 and based in Massachusetts, US, Aerovate Therapeutics, Inc. develops a pharmaceutical drug that helps in the treatment of pulmonary arterial hypertension. The company was founded by Dr. Benjamin T. Dake. Mr. Tim Noyes serves as the CEO of Aerovate Therapeutics, Inc. In August 2020, the company received its latest series A funding from a group of investors that included Atlas Venture, Sofinnova Ventures, and Surveyor Capital.

The company's product is called AV-101, an inhaled dry powder formulation of imatinib that helps in delivering the medicine to the diseased lung tissues while reducing systemic adverse effects. It provides treatment for pulmonary arterial hypertension and rare cardiopulmonary diseases.

The company's revenue is generated by the sales of its therapeutic drug called AV-101 to PAH patients and other related markets.

The company plans to become a publicly listed company in June 2021.

## Funding rounds

- Series A, Aug 6, 2020, $73M — Atlas Venture, Sofinnova Investments, OUP (Osage University Partners), Cormorant Asset Management, Surveyor Capital
- Seed, Jan 1, 2020 — RA Capital Management

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Seed
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Surveyor Capital — Series A